Direct to Patient Marketing: What Pharma Gets Wrong About Reaching Patients

Direct to patient marketing is the practice of communicating healthcare, pharmaceutical, or medical information directly to patients rather than routing everything through healthcare professionals. Done well, it shortens the path between a patient recognising a problem and getting effective treatment. Done badly, it burns budget reaching people who were never going to convert, while missing the ones who were.

The sector has a specific challenge that most consumer categories do not: the person you are marketing to is rarely the person who makes the final purchase decision. That asymmetry shapes everything, from channel selection to message architecture to how you measure success.

Why Most Direct to Patient Campaigns Start in the Wrong Place

I spent a good portion of my career in performance marketing, and for a long time I thought the lower funnel was where the real action was. Capture existing intent, optimise for conversion, report back impressive numbers. It took me years to properly interrogate what those numbers actually represented. In many cases, we were not generating demand. We were just being there when demand arrived anyway.

Direct to patient marketing in healthcare has the same problem, magnified. Most DTP programmes I have seen are built around patients who already know they have a condition, are already searching for treatment options, and are one step away from a GP conversation. That is a relatively small pool. The much larger opportunity sits with people who have symptoms but have not yet connected those symptoms to a diagnosable condition, or who have been diagnosed but have normalised their situation and stopped looking for better options.

Think about how many people live with poorly managed type 2 diabetes, undertreated depression, or chronic pain they have simply accepted as part of life. They are not searching for your brand. They are not in any intent signal you can easily capture. But they are the patients who, if reached effectively, represent genuine incremental volume rather than redistributed market share.

If you are building a go-to-market strategy for a healthcare product, the question is not just “how do we reach patients who are ready to ask about this?” It is “how do we reach patients who do not yet know they should be asking?” That is a fundamentally different brief, and it requires a fundamentally different channel mix. For a broader view of how this fits into commercial planning, the Go-To-Market and Growth Strategy hub covers the strategic frameworks that apply across sectors, including healthcare.

The Regulatory Environment Is Difficult, Not Impossible

Pharma marketers in the UK and Europe operate under ABPI and MHRA guidelines that restrict what you can say, how you can say it, and to whom. In the US, the FDA framework is different but equally specific. I am not going to pretend these constraints are trivial. They are not.

What I will say is that the constraints are frequently used as a reason to produce communications that are so hedged, so qualified, and so stripped of human relevance that they fail on basic marketing grounds before they even get to compliance review. I have sat in rooms where the legal team and the marketing team are essentially in opposition, and the output of that tension is content nobody wants to read.

The better approach is to involve regulatory and medical review earlier in the creative process, not at the end. When you brief a campaign knowing the guardrails, you can build ideas that work within them rather than ideas that have to be surgically altered afterwards. Disease awareness campaigns, patient support programmes, and unbranded condition education are all legitimate routes that can carry significant commercial weight without triggering the most restrictive requirements.

Forrester’s research on healthcare go-to-market challenges identifies regulatory complexity as one of the primary reasons healthcare companies underperform commercially. The finding is not that regulation prevents good marketing. It is that organisations have not built the internal capability to market effectively within a regulated environment. That is a solvable problem.

How the Patient experience Actually Works

Patient experience mapping is standard practice in healthcare marketing, and most of the maps I have seen are wrong in the same way. They start at diagnosis or at the point of active search. They treat the pre-awareness phase as someone else’s problem, usually public health or general brand advertising.

The reality is that the decision to seek help, the decision to mention symptoms to a doctor, the decision to push back on a “watch and wait” recommendation, all of those happen long before any intent signal appears in your analytics. A patient with rheumatoid arthritis may have had joint pain for two or three years before they connect it to an autoimmune condition. A patient with treatment-resistant depression may have cycled through two or three antidepressants before anyone raises the possibility of a different class of medication.

If your DTP marketing only activates once someone is already in the system and searching, you are competing for a smaller, more expensive pool of attention. The brands that build genuine patient relationships upstream, through condition education, symptom recognition content, and patient community engagement, are the ones that appear credible and familiar when the patient is finally ready to have the conversation with their clinician.

I saw a version of this dynamic play out clearly when I was working with a client in a considered-purchase category outside healthcare. We had poured budget into retargeting and paid search, and the numbers looked fine. But when we mapped the actual customer experience properly, we found that a significant proportion of converters had first encountered the brand through content that had nothing to do with our paid activity. The intent was already there when they hit our lower-funnel campaigns. We were measuring the last click and calling it the whole story. Healthcare DTP teams make the same mistake constantly.

Channel Strategy for Direct to Patient Campaigns

Channel selection in DTP has to follow the patient, not the marketer’s preference. That sounds obvious. In practice, most healthcare marketing teams have a channel heritage, usually TV, print, and digital display, and they allocate budget within that heritage rather than rebuilding from the patient’s actual media behaviour.

A few things worth being specific about:

Search remains the highest-intent channel in healthcare. When a patient is symptomatic and looking for answers, search is where they go first. The challenge is that most health searches happen at a condition or symptom level, not a brand level. Your paid search strategy needs to be built around the questions patients are actually asking, not the product features you want to promote. Condition-level content that ranks organically alongside paid activity gives you presence across the full funnel, not just at the bottom.

Social media is more useful than many pharma teams believe. The compliance nervousness around social is understandable, but it has led some organisations to abandon channels where their patients are genuinely active. Patient communities on Facebook, condition-specific forums, and health content on YouTube represent significant reach opportunities. what matters is understanding what you can say in each environment and building content that is genuinely useful rather than promotional in disguise.

Connected TV and audio are growing in relevance. As linear TV audiences fragment and streaming grows, the targeting capabilities available through connected TV allow healthcare brands to reach specific demographic and behavioural profiles with a level of precision that broadcast never offered. Combined with audio advertising through podcast placements in health and wellbeing content, there is a meaningful upper-funnel opportunity that is still underpriced relative to its reach.

HCP-adjacent channels matter more than most DTP strategies acknowledge. The patient and the prescriber are not in separate marketing universes. A patient who comes into a consultation having done their research, who can name the condition they think they have and the treatment options they want to discuss, changes the dynamic of that appointment. DTP marketing that equips patients to have better conversations with their clinicians is both more effective commercially and more defensible ethically.

What Good Patient Segmentation Actually Looks Like

Healthcare marketers talk about segmentation constantly and practice it inconsistently. The standard segmentation model in pharma tends to be clinical: diagnosed versus undiagnosed, treatment-naive versus treatment-experienced, adherent versus non-adherent. These are useful clinical categories. They are less useful as marketing segments because they tell you where someone is in a treatment pathway, not what they believe, what they fear, or what would actually move them to act.

Behavioural and attitudinal segmentation is harder to build, because it requires primary research rather than claims data, but it produces meaningfully better targeting. Patients who have accepted their condition as unmanageable need different messaging from patients who are actively looking for better options. Patients who distrust pharmaceutical companies need a different brand voice from patients who are already engaged with the healthcare system and looking for clinical information.

When I was growing an agency from around 20 people to just over 100, one of the consistent lessons from working across 30 different industries was that the organisations that invested in genuine audience understanding, not just demographic profiling, consistently outperformed those that relied on assumed knowledge. Healthcare is no different. The patient population for any given condition is not monolithic, and treating it as such is a reliable way to produce communications that resonate with nobody in particular.

BCG’s work on brand and go-to-market strategy makes the case that genuine audience alignment, not just channel optimisation, is where sustainable commercial advantage is built. That applies directly to DTP segmentation work.

Measuring Direct to Patient Marketing Honestly

Measurement in DTP is genuinely complex, and I want to be direct about that rather than pretend there is a clean solution. You are often working with fragmented data, privacy constraints, long conversion timelines, and a final transaction (a prescription) that happens in a setting you cannot directly observe.

The temptation is to fall back on proxy metrics that are easy to measure but weakly connected to commercial outcomes. Impressions, click-through rates, website sessions, video completion rates. These are not useless, but they are not results. I judged the Effie Awards, which are specifically focused on marketing effectiveness, and the entries that struggled most were the ones that could demonstrate activity but not impact. Healthcare brands are particularly vulnerable to this because the measurement environment is so difficult that teams sometimes stop trying to connect marketing to business outcomes at all.

What does honest measurement look like in practice? It involves triangulation rather than a single source of truth. Script lift data from pharmacy or IMS data, correlated with campaign timing and geography, gives you a directional signal on commercial impact. Patient-reported outcome surveys, run at a sufficient scale, can tell you whether your awareness and education programmes are actually changing knowledge and intention. HCP feedback, gathered through your medical science liaison network or through market research, can tell you whether the quality of patient conversations is changing.

None of these individually gives you a clean attribution model. Together, they give you an honest approximation of whether your marketing is working. That is what good measurement looks like in a complex environment. Not false precision, but honest triangulation.

Tools like Hotjar can provide behavioural insight on how patients interact with digital content, which is a useful input to understanding engagement quality even when downstream conversion data is inaccessible.

The Patient Support Programme as a Marketing Asset

Patient support programmes (PSPs) are often managed by medical affairs or patient services teams, sitting entirely outside the marketing function. That organisational separation means a significant commercial asset is frequently underutilised from a marketing perspective.

A well-designed PSP, one that genuinely helps patients manage their condition, adhere to treatment, and handle the healthcare system, is one of the most credible forms of brand communication available to a pharmaceutical company. It is evidence of commitment rather than a claim of it. Patients who participate in PSPs report higher satisfaction, better adherence, and greater likelihood of recommending both the treatment and the company to other patients.

The marketing implication is that PSP design should be informed by brand strategy, not just clinical protocol. The way a patient support programme communicates, the tone it uses, the channels it operates through, the frequency and nature of its touchpoints, all of these are brand expressions. If your DTP marketing is building a particular brand positioning and your PSP is communicating in an entirely different register, you have a coherence problem that will undermine both.

Bringing marketing into PSP design does not mean commercialising patient support. It means ensuring that every patient touchpoint is consistent, well-designed, and genuinely useful. That is a higher standard than most PSPs currently meet.

Where Creator and Influencer Strategy Fits in Healthcare DTP

Patient influencers, sometimes called health advocates or patient advocates, are a growing part of the DTP media landscape. People who live with chronic conditions and document their experience publicly have built substantial, highly engaged audiences of people in similar situations. From a reach and relevance perspective, they are an obvious opportunity.

The compliance complexity is real. Any paid partnership with a patient advocate who mentions a branded product triggers disclosure requirements and, in many markets, full promotional review. Unbranded disease awareness partnerships are more straightforward but require careful management to ensure the content does not stray into product endorsement territory.

The strategic question is whether the compliance overhead is worth it. In most cases, I think it is, provided the partnership is built around genuine content value rather than reach alone. A patient advocate who has spent five years building a community around managing a specific chronic condition has a level of credibility and trust that no pharmaceutical brand can replicate through paid media. Working with them to produce content that is genuinely useful to their audience, within appropriate disclosure frameworks, is a legitimate and effective DTP tactic.

Later’s resources on working with creators in go-to-market campaigns are worth reviewing for the general mechanics of creator partnership strategy, even if the healthcare application requires additional regulatory overlay.

The broader question of how DTP fits into your overall commercial growth strategy is one worth examining carefully. The Go-To-Market and Growth Strategy hub covers the strategic architecture that sits behind effective market entry and patient acquisition planning, with frameworks that translate directly into healthcare contexts.

Building a DTP Programme That Compounds Over Time

The most effective DTP programmes I have seen are not campaign-based. They are programme-based. There is a meaningful difference. A campaign has a start date, an end date, and a budget that runs out. A programme builds assets, audiences, and relationships that compound in value over time.

Practically, this means investing in owned media assets, particularly condition-specific content hubs and patient education resources, that continue to attract and inform patients long after the paid promotion behind them has stopped. It means building email and CRM relationships with patients who have opted in to receive information, so that you have a direct communication channel that does not depend on algorithm changes or media cost inflation. It means investing in patient community relationships and HCP education in parallel, so that the message patients receive from your brand is reinforced rather than contradicted by what they hear from their clinician.

BCG’s analysis on scaling agile approaches is relevant here in an unexpected way. The organisations that build compounding marketing programmes are the ones that treat patient engagement as an ongoing operational capability rather than a series of discrete campaign executions. That requires a different internal structure, different measurement cadences, and a different relationship between marketing and the rest of the business.

It also requires patience from commercial leadership. The payoff from a programme-based approach to DTP is real, but it arrives more slowly than a campaign spike. Making that case internally, with credible proxy data and a clear theory of how patient engagement translates to commercial outcomes, is part of the job.

Semrush’s overview of growth marketing approaches illustrates how compounding organic and content strategies outperform burst campaign activity over a 12 to 24 month horizon across multiple sectors. Healthcare is no exception to that pattern.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions